Precision diagnostics in brain health

Decoding brain biology through biomarkers in biofluids.

MedPrecis develops extracellular-vesicle biomarker technologies to support earlier, more personalised care in psychiatric and neurodegenerative disorders.

The problem

Brain health lacks objective diagnostics

  • In most of medicine, clinical evaluation is supported by objective tests.
  • In brain health, access to objective biological signals is limited.
  • Existing tools often provide late or non-specific information.

Our answer

Biology-based insight from a simple sample

  • Analyses organ-derived biological signals from simple biofluid samples (e.g. blood, urine, saliva…).
  • Captures disease mechanisms rather than isolated biomarkers.
  • Translates biology into interpretable outputs for clinical decision support.

Earlier detection · Stratification · Treatment guidance

Why it matters

Brain health is one of the great medical challenges of our time

~15%

of the Swiss population is affected by a mental health disorder.

~1 billion

people worldwide live with a mental disorder.

37%

of young people report mental health problems.

Neurodegenerative diseases are a growing challenge as populations age. In Switzerland, Alzheimer’s disease is the most common form, followed by Parkinson’s disease.

Source: World Health Organization (WHO).

Our approach

Bridging neuroscience and precision medicine

We translate advances in brain biology into biomarker solutions that support diagnosis, patient selection and therapeutic development — always alongside clinical expertise.

Brain-derived vesicles

Brain cells release extracellular vesicles that reach biofluids (e.g. blood, urine, saliva…), carrying molecular cargo from their cell of origin.

Two biomarker classes

Proteins and microRNA are measured from the same enriched vesicle fraction.

Rigorous by design

Particle normalisation, calibration curves, controls and batch tracking at every step.

Read our methodology →

Proven as a paid service

Already delivered as a paid analysis service in real-world research and clinical programmes, for leading academic centres and pharmaceutical partners.

Protected innovation

Patent families filed in Switzerland and the United States since 2019, covering key biomarkers, methods and clinical applications.

Global clinical network

An international network of clinicians and scientists supports validation and adoption.

Meet the team →

Our platforms

Four platforms, one vesicle-based science

Each platform applies extracellular-vesicle analysis to a different question — from brain disorders to systemic health.

Neurology & psychiatry

VESIBRAIN

A companion test that brings brain-derived vesicle biomarkers into the assessment of psychiatric and neurological disorders.

Discover VESIBRAIN →

Custom detection

VESIDX

A complete, flexible solution for custom detection — tailored assays for research and quality-control protocols.

Discover VESIDX →

Oncology

VESIPATH

Extracellular-vesicle analysis to explore the biological pathways of complex diseases, especially cancer.

Discover VESIPATH →

Systemic & multi-organ

VESIGEN

A systemic view of health, using vesicles as messengers that reflect the state of organs and cells.

Discover VESIGEN →

Applications

Supporting the next generation of therapeutic development

Patient stratification

Identify biologically meaningful patient subgroups to support precision-oriented clinical research.

Treatment-response research

Study molecular changes associated with therapeutic interventions and potential response biomarkers.

Translational biomarker development

Connect mechanistic neuroscience with biomarker discovery and clinical validation.

Full audience during a session on cognition and psychosis risk

Events

IMHC 2026 — 1st International Mental Health Conference

From help-seeking to precision medicine · 23–25 October 2026 · Tunis

See the highlights

Science-driven collaboration. Global ambition.

We work with academic researchers, clinical investigators, pharmaceutical companies and innovation partners to advance biomarker-driven neuroscience.

Start a collaboration